BMY Stock Price Today (September 2026) — Bristol-Myers Squibb Company Analysis & Key Metrics 2026-09-04
Bristol-Myers Squibb Company (BMY) is trading at $66.82, down 1.87% today (as of September 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $66.21 (-0.9% upside).
- Volatility remains elevated (21.30% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (5.70% YoY) alongside significant competitive pressures.
BMY Stock Analysis: Key Metrics & Valuation (September 2026)
Concise, actionable data for investors
Bristol-Myers Squibb Company - Historical Price & Volume
Market Cap
Enterprise Value: $169.99B
P/E Ratio
Forward P/E: 10.19
Revenue Growth
Year over Year
Analyst Target
+-0.9% upside potential
Key Investor Questions About BMY
What investors need to know before buying
Based on current market data, BMY presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 55.02)
- Fundamentals say: Caution warranted (high leverage concerns)
BMY's growth trajectory depends on its ability to expand within the Drug Manufacturers - General sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - General operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for BMY investors include debt exposure and competitive dynamics in the Drug Manufacturers - General industry.
- $45.05B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - General.
52-Week Trading Range
Over the past year, BMY stock traded between $42.52 and $68.64—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 21.30% annualized volatility and β=0.38, the stock exhibits low sensitivity to market moves—making BMY suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Wall Street Money Is Leaving Just As Atrium’s (RNA) Pipeline Turns Real
On August 13, Atrium Therapeutics (NASDAQ:RNA) reported second-quarter 2026 results that mixed real clinical progress with a familiar biotech question: how long the cash lasts. The company disclosed FDA clearance of its IND application for ATR 1072 and the launch of Corventis, its first Phase 1/2 trial and the first study anywhere testing a disease-modifying […]
Why Bristol Myers Squibb (BMY) Dipped More Than Broader Market Today
In the most recent trading session, Bristol Myers Squibb (BMY) closed at $66.82, indicating a -1.87% shift from the previous trading day.
Sector Update: Healthcare Stocks Decline Late Afternoon
Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index falling 1.2% and
Sector Update: Healthcare Stocks Decline Friday Afternoon
Healthcare stocks were lower Friday afternoon, with the NYSE Healthcare Index and the State Street H
Drugmakers Halt Autoimmune Trials After Deaths, Life-Threatening Side Effects
Trial freezes by Novartis and Bristol Myers have triggered a race to understand why a promising autoimmune treatment turned risky.
Market Chatter: Bristol Myers Squibb Paused Zola-Cel Trials Over Safety Concerns
Bristol Myers Squibb (BMY) has told regulators, researchers and patient groups in early June that it
Drugmakers Halt Autoimmune Trials After Deaths, Life-Threatening Side Effects
Trial freezes by Novartis and Bristol Myers have triggered a race to understand why a promising autoimmune treatment turned risky.
Is Merck Stock Pricing In A Post-Keytruda Future Too Soon?
Merck’s stock is the top performer in its group, but its profitability sits at the very bottom of the pack, forcing a hard question on investors.
Summit Therapeutics Says It Is Beating Merck With Its Cancer Drug
Summit says its ivonescimab is keeping lung-cancer patients alive longer than Keytruda does. The stock is up.
ABBV Stock Has Returned $62 Billion To Shareholders. Should You Care?
A pharma giant delivered substantial cash returns to shareholders while outperforming the broader market. Here is a breakdown of AbbVie's cash-return capacity, and the key commercial metric supporting its durability.
Explore More Analysis for BMY
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Frequently Asked Questions
Common investor questions about Bristol-Myers Squibb Company
Bristol-Myers Squibb Company (BMY) is currently trading at $66.82. The RSI (14-day) is at 55.0, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $66.21 implies 0.9% downside from current levels. Volatility is moderate at 21.3% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Bristol-Myers Squibb Company (BMY): The trailing P/E ratio is 14.72, which is below the market average of ~20-22, suggesting the stock may be undervalued relative to peers. The forward P/E is 10.19, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 2.37, above 2.0, suggesting the stock may be overvalued relative to its expected growth. Price-to-Book is 6.12. Price-to-Sales is 2.78. Valuation should be compared to Drug Manufacturers - General industry peers for context, as different sectors trade at different multiples.
Based on 24 analysts covering BMY, the consensus price target is $66.21. This represents a 0.9% downside from the current price of $66.82. The range spans from a low target of $40.00 to a high target of $80.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Bristol-Myers Squibb Company (BMY) pays a dividend with a current yield of approximately 3.77%. The annualized dividend rate is $2.51 per share. The payout ratio is 55.3%, which is moderate and suggests adequate earnings coverage for the dividend. The most recent ex-dividend date was 2026-07-02T00:00:00.000Z.
Key risks for Bristol-Myers Squibb Company (BMY) investors include: 1. Elevated debt levels (D/E ratio of 201.86) which could pressure margins in a rising rate environment. 2. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 3. Drug Manufacturers - General sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Bristol-Myers Squibb Company's (BMY) current debt and financial health profile: Total debt stands at $45.05B. The debt-to-equity ratio is 201.86, which is high and could pose financial risk if earnings decline or borrowing costs increase. The current ratio is 1.53, indicating strong short-term liquidity. The quick ratio is 1.29. The company holds $11.07B in cash and equivalents. Free cash flow is positive at $8.11B, providing a cushion for debt servicing and shareholder returns.